aTyr Pharma Q3 EPS $(0.20) Beats $(0.23) Estimate, Sales $353.00K Miss $1.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
aTyr Pharma reported Q3 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.23) by 13.04%. However, the company's quarterly sales of $353.00K missed the analyst consensus estimate of $1.50M by 76.47%.
November 09, 2023 | 9:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
aTyr Pharma's Q3 earnings beat estimates but sales fell short, which could lead to mixed market reactions.
While aTyr Pharma's Q3 earnings beat estimates, which is generally positive for the stock, the significant miss on sales could offset this positive impact. Investors may have mixed reactions to these results, leading to uncertain short-term price movements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100